Detalhe da pesquisa
1.
Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
Ophthalmology
; 123(7): 1521-9, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27157149
2.
Baseline Characteristics of the Fellow Eye in Patients with Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the VIEW Studies.
Ophthalmologica
; 236(2): 95-9, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27449643
3.
Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies.
Ophthalmol Retina
; 3(8): 663-669, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31103642
4.
Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies.
J Ophthalmol
; 2018: 3640135, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29785301
5.
Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Br J Ophthalmol
; 102(7): 954-958, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29051325
6.
Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Acta Ophthalmol
; 96(8): e911-e918, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29659183
7.
A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS).
Acta Ophthalmol
; 96(8): e942-e949, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29696809
8.
Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies.
Ophthalmol Retina
; 2(10): 988-996, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31047501
9.
First-dose effects with intravitreal aflibercept in wet age-related macular degeneration: a post-hoc analysis of VIEW-1 and VIEW-2 phase 3 studies.
Can J Ophthalmol
; 56(4): 268-269, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33249110